Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 7/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526215 | 1.00 | BDKRB2 (0.68) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30672603 | 0.99 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL31289571 | 0.99 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL31289572 | 0.98 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30672572 | 0.97 | BDKRB2 (0.72) | BDKRB2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL30549403 | 0.96 | BDKRB2 (0.63) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30526200 | 0.94 | BDKRB2 (0.61) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| Bradykinin SCHEMBL7949679 | 0.94 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1F2NMUR2 | |
| Bradykinin SCHEMBL7949684 | 0.94 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1F2NMUR2 | |
| SCHEMBL29496923 | 0.94 | BDKRB2 (0.62) | BDKRB2OPRM1OPRD1F2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118696052-A | Polyethylene glycol modifier of kinin or its derivative and its medicine application | 江苏众红生物工程创药研究院有限公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2023143246-A1 | POLYETHYLENE GLYCOL-MODIFIED FORM OF KININ OR DERIVATIVE THEREOF AND PHARMACEUTICAL USE THEREOF | 江苏众红生物工程创药研究院有限公司 | 2023-08-03 | — | — | WO | claimed |
| WO-2023143256-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD | 江苏众红生物工程创药研究院有限公司 | 2023-08-03 | — | — | WO | claimed |
| US-20250295792-A1 | POLYETHYLENE GLYCOL-MODIFIED FORM OF KININ OR DERIVATIVE THEREOF AND PHARMACEUTICAL USE THEREOF | ZONHON BIOPHARMA INSTITUTE, INC. (CN) | 2025-09-25 | — | — | US | disclosed |
| US-20250122257-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD | ZONHON BIOPHARMA INSTITUTE, INC. (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119584979-A | Use of kinin or derivatives thereof for the treatment of hypertension, prevention or treatment of complications of hypertension | 江苏众红生物工程创药研究院有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025021146-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATMENT OF HYPERTENSION AND PREVENTION OR TREATMENT OF HYPERTENSION COMPLICATIONS | 江苏众红生物工程创药研究院有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119367503-A | Use of kinin or derivatives thereof for the treatment of hypertension, prevention or treatment of complications of hypertension | 江苏众红生物工程创药研究院有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4471154-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD | Zonhon Biopharma Institute, Inc. (CN) | 2024-12-04 | — | — | EP | disclosed |
| EP-4471050-A1 | POLYETHYLENE GLYCOL-MODIFIED FORM OF KININ OR DERIVATIVE THEREOF AND PHARMACEUTICAL USE THEREOF | Zonhon Biopharma Institute, Inc. (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118696052-A | Polyethylene glycol modifier of kinin or its derivative and its medicine application | 江苏众红生物工程创药研究院有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118541172-A | Use of kinin or derivatives thereof for the treatment of VCI, PSCI or CSVD | 江苏众红生物工程创药研究院有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4348265-A2 | DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-04-10 | — | — | EP | disclosed |
| CN-116554267-A | Polyethylene glycol modified kinin or variant thereof and pharmaceutical use thereof | 江苏众红生物工程创药研究院有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116549599-A | Use of kinin and its derivatives in the treatment of VCI, PSCI or CSVD | 江苏众红生物工程创药研究院有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023143256-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD | 江苏众红生物工程创药研究院有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143246-A1 | POLYETHYLENE GLYCOL-MODIFIED FORM OF KININ OR DERIVATIVE THEREOF AND PHARMACEUTICAL USE THEREOF | 江苏众红生物工程创药研究院有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-110088627-B | Biomarkers | 大诺牛津科学有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-1926136-A | Amino cyclopropane carboxamide derivatives as bradykinin antagonists | MERCK & CO INC (US) | 2007-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122257-A1 | USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD | NSD1, PNMT, NSD2 | BDKRB2 504/4885OPRM1 795/4885OPRD1 223/4885 |
| US-20250295792-A1 | POLYETHYLENE GLYCOL-MODIFIED FORM OF KININ OR DERIVATIVE THEREOF AND PHARMACEUTICAL USE THEREOF | PLG, KLKB1, BDKRB2 | BDKRB2 3/4885OPRM1 857/4885OPRD1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.